Pitrou and colleagues demonstrate why it is important to do research that evaluates the quality of studies that guide clinical decision-making – specifically, to examine how information is presented in medical journals. The subject under the spotlight in their study is how authors report adverse drug reactions. The importance of this effort stems from the knowledge that adverse drug reactions are a substantial source of morbidity and mortality.1 We have become accustomed to pharmaceutical companies promoting their drugs directly to consumers with bold promises of efficacy that contrast with the rapidly spoken, end of message, small font reminders of the …